Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Faster onset of action" claim for S(+)ibuprofen could inform consumers, cmte. notes.

This article was originally published in The Tan Sheet

Executive Summary

S(+)IBUPROFEN "FASTER ONSET OF ACTION" CLAIM would provide useful information to consumers, several members and consultants to FDA's Nonprescription Drugs and Arthritis Drugs Advisory Committees agreed at an Oct. 9 joint meeting. Bayer is claiming that S(+)ibuprofen, or dexibuprofen, has a faster onset than racemic, or regular, ibuprofen. The joint advisory committee decided at the one-day meeting not to recommend that FDA approve Bayer's NDA for dexibuprofen as an OTC nonsteroidal anti-inflammatory drug based on Bayer's submitted safety and efficacy data.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086209

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel